A recently completed Phase III trial – called PREEMPT – established the efficacy and safety of onabotulinumtoxinA (marketed by Allergan under the brand name Botox®) in treating chronic migraine. Following those results, a new long-term trial is currently underway to analyze some of the clinical questions raised but not answered in PREEMPT.
Patients with idiopathic generalized epilepsies (IGE) can also have focal seizure symptoms. A team of Australian researchers has added some findings that indicate which patients are more likely to have both types of seizures
From working in the wilderness to waiting at the finish line of some of the most extreme races around the country doctors are going as far from the medical offices as their patients do in order to provide the best level of service possible.